DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Luseogliflozin
Luseogliflozin
Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
Effect of Luseogliflozin on Bone Microarchitecture in Elderly Patients with Type 2 Diabetes
202293Orig1s000
Glomerular Hyperfiltration in Diabetes
Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment
(SGLT2) Inhibitors: a Systematic Review and Meta-Analysis
Dapagliflozin- Induced Severe Ketoacidosis Requiring Hemodialysis Ossama Maadarani*, Zouheir Bitar and Rashed Alhamdan
Comparison of the Efficacy and Safety of 10-Mg Empagliflozin Every Day Versus Every Other Day in Japanese Patients with Type 2 Diabetes Mellitus : a Pilot Trial
Type 2 Diabetes Screening and Treatment Guideline | Kaiser
Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three Sglt2 Inhibitors in Type 2 Dm Subjects
Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Adverse Renal Outcomes
Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake
SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
Susceptibility to Serious Skin and Subcutaneous Tissue Disorders And
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Comparative Effectiveness of Sodium- Glucose Co-Transporter 2 Inhibitors
Adverse Effects and Safety of SGLT2 Inhibitor Use Among Patients with Type 2 Diabetes: Findings from RCT Evidence
Diabetes Mellitus (1 of 42)
Top View
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
Pharmaceutical Composition for Preventing Or Treating Diabetes, Containing Zinc Salt, Cyclo-Hispro and Antidiabetic Drug As Active Ingredients
Clinical Therapeutics/New Technology— Glucose Monitoring and Sensing 2348‑Pub
Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C26457869-01
Drug Interactions of Sglt2 Inhibitors (Gliflozins) Involving Ugt Enzymes Dr
Type 2 Diabetes Mellitus That Is Hitting Back With
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Australasian Anaesthesia 2019
3/23/2015 1 Medications Update – New and Emerging Therapies
(12) Patent Application Publication (10) Pub. No.: US 2013/0137646 A1 WENRICH Et Al
A Literature Review and Meta-Analysis of Safety Profiles of SGLT2 Inhibitors
Late Breaking Abstracts July 2013 | Volume 62 | Suppl
RFP) Significant Renal Protection Was Observed of Sglt2i Over Placebo2
Characterization and Comparison of Sodium-Glucose Cotransporter 2 Inhibitors in Pharmacokinetics, Pharmacodynamics, and Pharmacologic Effects
The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT
The Effect of Luseogliflozin on Bone Microarchitecture in Older Patients with Type 2 Diabetes
The Association Between the Dosage of SGLT2 Inhibitor and Weight
The Effect of Luseogliflozin and Alpha- Glucosidase Inhibitor on Heart
Safety, Pharmacokinetics, and Pharmacodynamics Of
Beneficial Effects of SGLT2 Inhibitors on Fatty Liver in Type 2 Diabetes: a Common Comorbidity Associated with Severe Complicati
A Complete Review of Empagliflozin
Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients with Type II Diabetes Mellitus: a Systematic Review
12-Cem-Diabetes-Hand
Effects of SGLT-2 Inhibitors on Mortality and Cardiovascular Events: a Comprehensive Meta-Analysis of Randomized Controlled Trials
Exercise Testing in Individuals with Diabetes, Practical Considerations for Exercise Physiologists
Sodium–Glucose Transporter-2 Inhibitors for Prevention And
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Type 2 Diabetes Mellitus 2014